Teeple, A, and E Muser. “Cost Per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients With Moderate to Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S80. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/477.